Nuclear DNA and associated oncogenic signaling networks

The term Nuclear DNA and associated oncogenic signaling networks encompasses the totality of the cell's genetic blueprint and the interconnected biochemical pathways that translate external stimuli into cellular responses, particularly those driving cancer. Nuclear DNA is the site of genetic storage and transcription, frequently targeted by traditional chemotherapeutics to induce lethal damage in rapidly dividing cells (Reference: PubMed, PMCID: PMC3108293). Associated oncogenic signaling networks, such as the Ras-Raf-MEK-ERK and PI3K-AKT-mTOR pathways, are frequently hyperactivated in tumors, leading to uncontrolled growth and survival (Reference: Nature Reviews Molecular Cell Biology). These networks function as a complex communication system, relaying signals from the cell surface to the nucleus to modulate gene expression. Modern oncology focuses on both direct DNA intervention and the precise inhibition of these signaling nodes to disrupt the oncogenic phenotype. Drugs targeting DNA include alkylating agents and platinum-based compounds, while signaling inhibitors target specific kinases like EGFR or BRAF (Reference: NIH National Cancer Institute). However, the complexity and redundancy of these networks often necessitate combination therapies to overcome inherent or acquired resistance (Reference: CA: A Cancer Journal for Clinicians). Therapeutic challenges include significant systemic toxicity and the emergence of bypass mutations that restore signaling flow.

Other names

Genomic DNAOncogenic signaling pathwaysCancer genome and signaling networks

DNA alkylation, DNA intercalation, inhibition of topoisomerases, and competitive inhibition of oncogenic kinases within signaling cascades.